Trial · NCT00410189

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

NCT00410189, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2015-03-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC. Trials, record NCT00410189. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00410189

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
NCT number: NCT00410189
Status: Completed
Phases: Phase 2
Enrollment: 54 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Lung Cancer
Interventions: ZD6474
First posted: 2006-12-12
Last updated: 2015-03-23
Results first posted: 2015-03-23

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	8-Week Disease Control Rate (Complete Response, Partial Response and Stable Disease)	Baseline to 8 Weeks	The disease control rate (DCR) is the percentage of patients without progression at 8 weeks. Disease control rate defined as: Complete Response (CR): Disappearance of all non-target/target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.
Secondary	8 Week Progression-Free Survival	Every 8 weeks till disease progression.	Progression-free survival (PFS) was estimated using Kaplan-Meier method. PFS was defined as time from start of treatment to disease progression.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	8 Week Progression-Free Survival	Every 8 weeks till disease progression.		months	MEDIAN
PRIMARY	8-Week Disease Control Rate (Complete Response, Partial Response and Stable Disease)	Baseline to 8 Weeks		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
8 Week Progression-Free Survival	ZD6474		1.81	Full Range 0.16 to 23.46	months
8-Week Disease Control Rate (Complete Response, Partial Response and Stable Disease)	ZD6474		33		percentage of participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	ZD6474	54
Overall Study	COMPLETED	ZD6474	54
Overall Study	NOT COMPLETED	ZD6474	0

Source ClinicalTrials.gov

Adverse events257

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abnormal Electrolytes	Renal and urinary disorders	ZD6474	25	54	25
other	Constitutional Symptoms	General disorders	ZD6474	24	54	24
other	Diarrhea	Gastrointestinal disorders	ZD6474	24	54	24
other	Elevated Alkaline Phosphatase	Metabolism and nutrition disorders	ZD6474	22	54	22
other	Abnormal Liver Enzymes	Hepatobiliary disorders	ZD6474	19	54	19
other	Hypertension	Cardiac disorders	ZD6474	18	54	18
other	Rash	Skin and subcutaneous tissue disorders	ZD6474	11	54	11
other	Anorexia	Gastrointestinal disorders	ZD6474	15	54	15
other	Hyperglycemia	Metabolism and nutrition disorders	ZD6474	15	54	15
other	Pain	General disorders	ZD6474	5	54	5

1 to 10 of 257Source ClinicalTrials.gov

See all 257 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	ZD6474
Total, other adverse events	ZD6474	54	54
Total, serious adverse events	ZD6474	54	54

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
22586319	DERIVED	PubMed
23442309	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00410189

GET https://conductscience.org/api/trials/v1/NCT00410189/events?page=2

API reference For AI assistants